Watson Pharmaceuticals, Inc. (WPI) Reports Third Quarter 2009 GAAP EPS of $0.55; Adjusted EPS of $0.66
11/4/2009 8:09:59 AM
More...
|
Watson Pharmaceuticals, Inc. (WPI): New Data Suggest that GELNIQUE(R) (oxybutynin chloride) gel 10% Does Not Impact Cognition among Healthy Older Adults
9/29/2009 8:41:02 AM
More...
|
Watson Pharmaceuticals, Inc. (WPI) Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use
8/31/2009 8:20:13 AM
More...
|
Fitch Rates Watson Pharmaceuticals, Inc. (WPI)'s Proposed Sr. Unsecured Notes 'BBB-'; Affirms IDR at 'BBB-'
8/18/2009 10:04:40 AM
More...
|
Watson Pharmaceuticals, Inc. (WPI) Announces Offering of Senior Unsecured Notes
8/18/2009 8:29:39 AM
More...
|
Watson Pharmaceuticals, Inc. (WPI) (JOBS) Sees Windfall as Toprol XL Generic Wins OK
8/4/2009 6:25:07 AM
More...
|
Watson Pharmaceuticals, Inc. (WPI) Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
7/29/2009 8:55:23 AM
More...
|
Watson Pharmaceuticals, Inc. (WPI) CFO Mark W. Durand to Take Leave of Absence
7/28/2009 9:42:31 AM
More...
|
Watson Pharmaceuticals, Inc. (WPI) Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)
7/15/2009 8:59:16 AM
More...
|
Watson Pharmaceuticals, Inc. (WPI) Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) NDA; FDA Requests More Data
7/14/2009 7:02:01 AM
More...
|
|